July 14, 2025 09:30 AM EDT
R&D
Pharma

Mer­ck sends new month­ly oral PrEP to Phase 3 af­ter ear­li­er is­la­travir set­back

Kyle LaHucik

Biotech Correspondent

KI­GALI, RWAN­DA — Three years af­ter a safe­ty dis­ap­point­ment halt­ed ear­li­er plans for a once-month­ly HIV PrEP can­di­date, Mer­ck is back in the late stages of …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

23andMe files for bank­rupt­cy, CEO Wo­j­ci­c­ki steps down

Re­gen­eron plans to buy 23andMe for $256M

FDA de­clines to ap­prove Ul­tragenyx's San­fil­ip­po gene ther­a­py, cit­ing man­u­fac­tur­ing is­sues

23and­Me's CEO files plan to take com­pa­ny pri­vate

FDA chief calls for low­er user fees as ne­go­ti­a­tions be­gin for eighth round of PDU­FA

Af­ter long saga, 23and­Me's deal with Anne Wo­j­ci­ck­i's non­prof­it fi­nal­ly clos­es

A service from the Financial Times